logo
Plus   Neg
Share
Email

SEC Finds Activist Investor Li Didn't Disclose Key Facts On Holdings Of Sinovac

Sinovac Biotech Ltd. (SVA), a provider of biopharmaceutical products in China, said that the United States Securities and Exchange Commission charged activist investor, Jiaqiang "Chiang" Li and his firm 1Globe Capital LLC based on their failure to disclose the full amount of Sinovac shares they beneficially owned and their participation in an activist plan to replace the majority of Sinovac's Board of Directors.

The SEC order found that Li and 1Globe violated United States federal securities laws and SEC rules requiring individuals or entities whose total ownership of a company's stock exceeds certain thresholds to disclose their ownership, intention to acquire additional shares, and plans regarding changes in company management or control.

Li and 1Globe agreed to the entry of the SEC's order without admitting or denying the SEC's findings of violations and agreed to pay civil penalties totaling $290,000.

According to Sinovac, the SEC's findings align with both the factual findings of Sinovac's Board in triggering the company's Rights Agreement and with previous findings by the High Court of Justice of Antigua and Barbuda, where Sinovac and 1Globe are engaged in ongoing litigation.

The SEC found that Li and 1Globe participated in an activist plan to replace four of five incumbent directors through a shareholder vote at Sinovac's 2018 annual shareholder meeting in Beijing but failed to disclose material information.

Sinovac stated that the SEC decision highlighted how Li and 1Globe's illegal and improper actions negatively impacted Sinovac's shareholders and reaffirms factual determinations made by the current rightfully elected directors of Sinovac.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
RELATED NEWS
Follow RTT